Powered By LookupPage LookupPage
Join LookupPage    

Fred Colen

Former President, CRM Group
Boston Scientific

33064, United States

Contact Fred Colen Directly

Contact Directly

About Fred Colen

Mr. Fred Colen served as an executive for Boston Scientific Corporation, a leading manufacturer of medical technologies, for 11 years. Among his many roles with the company, Mr. Colen served as President of the Cardiac Rhythm Management Group. In addition to his efforts to revitalize the division, he overcame quality and regulatory issues and resolved a warning letter from the Food and Drug Administration in just more than a year’s time. As President, Mr. Colen was responsible for $2.4 billion worth of global business, drastically improved the division’s operational efficiency, introduced important new products, and sponsored a MADIT-CRT Clinical study that led to the FDA approval of CRT-D treatment for early-stage heart failure.


As Senior Vice President of Cardiovascular Research and Development and as Chief Technology Officer for Boston Scientific, Fred Colen created, developed, and introduced to the global market the Taxus brand of drug-eluting stents, which generated more than $2 billion annual revenue for the company. During this time, he reported directly to the CEO on all matters regarding technology and product development, overseeing a budget that grew from $250 million to $1 billion over the course of 7 years. Fred Colen brought decades of invaluable experience to his role at BSC. From 1994 to 1998, he worked for St. Jude Medical, Inc. As Executive Vice President of the company’s Los Angeles-based subsidiary Pacesetter, Inc., Mr. Colen took charge of the $45 million annual R&D budget of the cardiac rhythm management business and headed up product planning and medical services.


At the same time, he oversaw a manufacturing and research and development facility in Stockholm, Sweden and headed up 430 employees. Fred Colen introduced the concept of Fast Cycle Time, a research and development process that optimized new product introductions and decreased cycle times of development. Mr. Colen also spearheaded the construction of an R&D and manufacturing facility that improved efficiency, tripled manufacturing capacity, and boosted the company’s profit.


He also spent nearly a decade with Lewicki Microelectronic GmbH, and eight years with Cardiac Pacemakers, Inc. Fred Colen possesses a Bachelor of Electrical Engineering and a Master’s of Electrical Engineering, which he earned at the Eindhoven University of Technology in The Netherlands, and the University of Aachen in Germany, respectively. Mr. Colen speaks English, Dutch, and German fluently and understands French and Swedish. A citizen of the Netherlands, Mr. Colen holds permanent resident status in the United States.




Boston Scientific

Former President, CRM Group

Medical Devices

Natick, MA

08/1/1999 — 07/1/2010


Successfully turned CRM Division around, overcoming severe Quality and Regulatory issues and clearing FDA warning letter in 14 month time, dramatically increased operational efficiency, introduced exciting new products, sponsored landmark MADIT-CRT Clinical study, which led to new FDA indication for CRT-D treatment of early stage heart failure and achieved double digit revenue growth in 2009 and 2010 of this $2.4B global business. 




Technical University Aachen, Germany

Bio-Medical Engineering

Masters Electrical Engineering

Aachen, DE

09/1/1971 — 11/1/1977 




Sailing, Power-Boating, skiing, hiking, golfing, reading and singing.

Fred Colen Links

Contact Information
Not available
LookupPage Directory
  Search other Lookup Pages like
Fred Colen
LookupPage | Enhanced Online Visibility